Skip to main content
. 2022 Aug 24;14(9):1768. doi: 10.3390/pharmaceutics14091768
ADCC Antibody-Dependent Cell-Mediated Cytotoxicity
AML Acute Myeloid Leukemia
BTK Bruton Tyrosine Kinase
CDK Cycle-dependent Kinase
CLL Chronic Lymphatic Leukemia
CRC Colorectal Cancer
DC Dendritic Cells
DDR DNA Damage Repair
DNMT DNA Methyltransferase
DTC Differentiated Thyroid Cancer
HCC Hepatocellular Carcinoma
HDAC Histone Deacetylases
HNSCC Head and Neck Squamous Cell Carcinoma
ICI Immune Checkpoint Inhibitor
MCL Mantel Cell Lymphoma
MDSC Myeloid Derived Suppressor Cells
NK Nature Killer Cells
NSCLC Non-small Cell Lung Cancer
ORR Objective Response Rate
OS Overall Survival
PDAC Pancreatic Ductal Adenocarcinoma
PFS Progression-free Survival
PTC Papillary Thyroid Carcinoma
RCC Renal Cell Carcinoma
TAM Tumor-associated Macrophages
TGF-β transforming growth factor-β
TIB Tumor-infiltrating B Cells
TIME Tumor Immune Microenvironment
TKI Tyrosine Kinase Inhibitor
TNBC Triple-negative Breast Cancer